Cybin can now begin a phase 1/2a double-blind, placebo-controlled trial. In it, Participants will receive two administrations (placebo/active and active/active) and response will be evaluated at week 3 (after first dose) and at Week 6 (after second dose).
The company expects to have an interim pharmacokinetic and safety data readout in Q4.